Innate pharma presents lacutamab improved health-related quality of life data at ash 2024 from tellomak phase 2 study in patients with cutaneous t cell lymphoma

Marseille, france--(business wire)-- #anket--regulatory news: innate pharma sa (euronext paris: iph; nasdaq: ipha) (“innate” or the “company”) today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous t-cell lymphoma (ctcl) treated with lacutamab in the tellomak phase 2 clinical study. these data were presented at the 66th american society of hematology (ash) annual meeting in san diego, california. the tellomak study addresses a critical unmet need for p.
ASH Ratings Summary
ASH Quant Ranking